Card image cap
Top drug makers now focus on ‘long Covid’ therapies

World’s leading drugs and pharmaceutical companies, including GlaxoSmithKline, Pfizer, Roche, among others who have already researched and launched vaccines,  antiviral pills and monoclonal antibody treatments for Covid-19, are now focussing on therapies that can address ‘long Covid’, said the latest news report by  Reuters filed from London and Chicago.  The condition of long Covid, which is defined as persisting symptoms including fatigue, chest pain and brain fog, heart problems, lungs and respiratory issues beyond three months after the virus infection, has been widely reported among Covid survivors from across the world.

Elevate your practice with our advanced AI-based CDSS Tool.Transform your practice now!

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Submit a Comment